Cover Image
Market Research Report
Product code 
1080938

Middle East Liquid Biopsy Market - Country Analysis: Focus on Product, Technology, Indication, Sample, Workflow, Circulating Biomarker, Usage, and Country Data - Analysis and Forecast, 2022-2032

Published: | BIS Research Inc. | 170 Pages | Delivery time: 1-2 business days

Price

Back to Top
Middle East Liquid Biopsy Market - Country Analysis: Focus on Product, Technology, Indication, Sample, Workflow, Circulating Biomarker, Usage, and Country Data - Analysis and Forecast, 2022-2032
Published: May 19, 2022
BIS Research Inc.
Content info: 170 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Middle East Liquid Biopsy Market to Reach $175.2 Million by 2032

Middle East Liquid Biopsy Market: Industry Overview

In 2021, the Middle East liquid biopsy market was valued at $43.7 million, and it is expected to reach $175.2 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032. The Middle East liquid biopsy market is expected to witness high growth due to the rising incidence of cancer, the increasing fund infusions for conducting research to discover novel biomarkers, and the growing emphasis on the use of non-invasive methodologies for performing a liquid biopsy. The constant significant investments by healthcare companies to meet industry demand and the increasing adoption of liquid biopsy among major end users are significant factors propelling the growth of the Middle East liquid biopsy market.

Market Lifecycle Stage

A liquid biopsy is an emerging approach for disease treatment and prevention that considers individual variability in genes, environment, and lifestyle for each person. The ultimate goal of liquid biopsy is to provide the right treatment, to the right patient, at the right time. The liquid biopsy research is being conducted for several disease areas such as oncology, immunology, neurology, and infectious diseases. Liquid biopsy is one of the most modernized trends in the healthcare industry, which has shown tremendous progress in 2019-2021. The use of non-invasive liquid biopsy for analyzing fetal cell-free DNA (cfDNA) can offer critical information, which could tell the physician and the mother whether to continue a pregnancy or not. In addition, research is also being conducted to assess the clinical potential of extracellular vesicles (EVs) to screen metabolic disorders, including diabetes. It is worth mentioning here that EVs contain nucleic acids, particularly microRNA (miRNA), which is an excellent source to monitor the progression of metabolic disorders. With the incorporation of molecular technologies, researchers and clinicians could offer insights regarding the onset of metabolic disorders and the early diagnosis of diabetes-related microvascular complications in patients. Significant fund infusions are being provided to companies and academic research institutes to examine the potential of circulating nucleic acids present in the non-invasive samples, which could offer massive opportunities to the Middle East liquid biopsy market in the forthcoming years.

Impact

  • The presence of major service providers of liquid biopsy products in the Middle East region has a significant impact on the market. For instance, Illumina, Inc. provides NovaSeq 6000 S2, Reagent Kit, NovaSeq 6000 S4 reagent kit, and NovaSeq Xp 4-lane kit in the Middle East.
  • Companies such as F. Hoffmann-La Roche Ltd offer FoundationOne Liquid. It is a U.S. Food and Drug Administration-approved product that assesses guideline-recommended genes from a simple blood draw method. It is the only FDA-approved blood-based test that analyzes more than 300 genes. The presence of such products has a positive impact on market growth.

Impact of COVID-19

The current Middle East liquid biopsy market study comprises products and services utilized to analyze underlying alterations in circulating biomarkers from non-invasive sample types. Since the market is primarily dominated by the clinical utility of products and services, the COVID-19 pandemic had a high impact on the growth and revenue generated from the market. The current market assessment has considered information provided by key opinion leaders in the market from both supply and demand sides. Although manufacturers have witnessed low-scale losses due to decreased demand, the losses incurred for the first two quarters of FY2020-2021 are anticipated to be compensated by higher demands in the following two quarters in FY2021.

However, the industry is still expected to be impacted significantly during the period 2020-2022. The low influx of cancer patients in hospitals and diagnostic laboratories has massively impacted the sales of Exact Sciences' Cologuard test. In 2020, Exact Sciences Corporation was the market leader in the non-invasive liquid biopsy ecosystem, having a 74.31% share in the Middle East liquid biopsy market. Some respondents also stated that they had to delay their product launches due to the ensuing restrictions, which massively impacted market growth. Nevertheless, they are still planning to launch the respective products within theFY2021. As of the current situation, strategies to bolster sales in the last two quarters in order to negate the impact of the COVID-19 pandemic invariably include aggressive marketing and discounted prices offered for existing portfolios. It is expected that, with the restrictions gradually being removed from several regions around the world, coupled with research activities resuming normalcy, the market will face a low impact on the annual revenue generation.

Market Segmentation

Segmentation 1: by Technology

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Fluorescence In-Situ Hybridization (FISH)
  • Other Technologies

The Middle East liquid biopsy market (by technology) was dominated by the next-generation sequencing (NGS) segment in 2021. The highest share of NGS can be attributed to an increase in demand for oncology assessment. This is due to the increasing prevalence of cancer, and due to this, the major share of liquid biopsy is expected to be held by NGS.

Segmentation 2: by Workflow

  • Sample Preparation
  • Library Preparation
  • Sequencing
  • Data Analysis

In 2021, the library preparation segment dominated the Middle East liquid biopsy market (by workflow) due to an increasing number of patients suffering from cancer. According to the data published by the World Health Organization, cancer is a leading cause of death, with nearly 10 million deaths reported in 2020.

Segmentation 3: by Usage

  • Research Use Only (RUO)
  • Clinical

The Middle East liquid biopsy market (by usage) was dominated by the research use only segment in 2021. This growth was attributed to the academic research and industry collaboration in the Middle East region. Moreover, the technological advancement in RUO products is boosting the growth of the Middle East liquid biopsy market.

Segmentation 4: by Sample

  • Blood
  • Urine
  • Saliva
  • Cerebrospinal Fluid

In 2021, the Middle East liquid biopsy market (by sample) was dominated by the blood segment owing to an increasing number of patients suffering from different cancers.

Segmentation 5: by Circulating Biomarker

  • Circulating Tumor Cells (CTCs)
  • Cell-Free DNA (cfDNA)
  • Circulating Cell-Free RNA
  • Exosomes and Extracellular Vesicles
  • Other Circulating Biomarkers

The Middle East liquid biopsy market (by circulating biomarker) in 2021 was dominated by the cell-free DNA segment due to an increasing number of research studies pertaining to liquid biopsy segment.

Segmentation 6: by Product

  • Tests/Services
  • Kits and Consumables
  • Instruments

The tests/services segment dominated the Middle East liquid biopsy market (by product) in 2021 due to the continued significant investments by healthcare companies to meet industry demand for tests/services, and the growing adoption of liquid biopsy tests among major end users were the key factors propelling the growth of the segment.

Segmentation 7: by Country

  • K.S.A.
  • Israel
  • Egypt
  • U.A.E.
  • Iran
  • Qatar
  • Rest-of-the-Middle East

The K.S.A. generated the highest revenue of $13.5 million in 2021, which is attributed to the R&D advancements in the field of single-cell analysis and the presence of dominating players operating in the Middle East liquid biopsy market.

Recent Developments in Middle East Liquid Biopsy Market

  • In October 2020, Bio-Rad Laboratories launched the CFX Opus 96 Dx System and CFX Opus 384 Dx System. The product could multiplex about five samples to offer effective in-vitro diagnostics (IVD) assay development and testing. The product has been commercialized in the Middle East region.
  • In March 2021, F. Hoffmann-La Roche Ltd released the AVENIO Tumor Tissue CGP Kit, enabling laboratories to extend their oncology research in-house.
  • In June 2019, F. Hoffmann-La Roche Ltd partnered with the Health Authority and an international health insurer, AXA, in Dubai. This partnership would develop funding for diagnostic and treatment for breast, colorectal, and cervical cancers.

Demand - Drivers and Limitations

Following are the demand drivers for the Middle East liquid biopsy market:

  • Liquid Biopsy Demand Inclined by Rising Prevalence of Cancer
  • Rise in Patient Preference for Non-Invasive Cancer Diagnosis
  • Potential of Liquid Biopsy

The market is expected to face some limitations too due to the following challenges:

  • False Negatives and Positives
  • Existing Diagnostic Confidence in Traditional Tissue-Based Diagnosis Practices

How Can This Report Add Value to An Organization?

Product/Innovation Strategy: The product segment helps the reader understand the types of products, i.e., tests/services, kits and consumables, and instruments. These ecosystems are the primary focus of the study as these are the target of market players in terms of revenue generation. Moreover, the study provides the reader with a detailed understanding of the different applications such as lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, other cancers, and non-oncology disorders.

Growth/Marketing Strategy: The Middle East liquid biopsy market has been dominated significantly by companies such as QIAGEN N.V., PerkinElmer, Inc., F. Thermo Fisher Scientific Inc., and Hoffmann-La Roche Ltd., due to their expansive portfolio and strong geographical presence across the world. Many companies such as Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer, Inc., Beckman Coulter, Inc. (Danaher Corporation), Illumina, Inc., and Bio-Rad Laboratories, Inc. lie in the low growth and low market share segment. Most key market players in the Middle East liquid biopsy market are categorized under the low growth and low market share segment. The low market share of these companies is primarily due to limited products with respect to the Middle East liquid biopsy market in comparison to other segments of these companies. Also, the lack of synergistic activities with respect to the market is responsible for the low growth of these companies.

Competitive Strategy: Key players in the Middle East liquid biopsy market analyzed and profiled in the study have involved the oncology application-based product manufacturers that provide liquid biopsy tests and services. Moreover, a detailed competitive benchmarking of the players operating in the Middle East liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Bio-Rad Laboratories, Inc.
  • Bioscience Institute S.p.A.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: BHP1225SA

Table of Contents

1 Middle East Liquid Biopsy Market

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion
    • 1.1.2 Key Questions Answered in the Report
  • 1.2 Research Methodology
    • 1.2.1 Primary Data Sources
    • 1.2.2 Source: BIS Research Analysis Secondary Data Sources
  • 1.3 Market Estimation Model

2 Market Overview

  • 2.1 Market Definition
  • 2.2 Emerging Applications of Liquid Biopsy
  • 2.3 Market Footprint and Growth Potential, $Million, 2021-2032
  • 2.4 COVID-19 Impact on the Middle East Liquid Biopsy Market

3 Industry Insights

  • 3.1 Patent Analysis
    • 3.1.1 Key Players Patent Portfolio
    • 3.1.2 Patent Filing Analysis
    • 3.1.3 Key Players Patent Expiration Analysis
  • 3.2 Legal Requirements and Regulations

4 Competitive Landscape

  • 4.1 Key Strategies and Developments
    • 4.1.1 Agreement and Partnership
    • 4.1.2 Regulatory Accreditations
    • 4.1.3 Product and Service Launches
    • 4.1.4 Mergers and Acquisitions
    • 4.1.5 Approvals

5 Market Dynamics

  • 5.1 Market Dynamics
    • 5.1.1 Impact Analysis
  • 5.2 Market Drivers
    • 5.2.1 Liquid Biopsy Demand Inclined by Rising Prevalence of Cancer
    • 5.2.2 Rise in Patient Preference for Non-Invasive Cancer Diagnosis
    • 5.2.3 Potential of Liquid Biopsy
  • 5.3 Market Restraints
    • 5.3.1 False Negatives and Positives
    • 5.3.2 Existing Diagnostic Confidence in Conventional Tissue-Based Diagnosis Practices
  • 5.4 Market Opportunities
    • 5.4.1 Potential Cost Savings
    • 5.4.2 Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy

6 Middle East Liquid Biopsy Market, by Product, $Million, 2022 - 2032

  • 6.1 Overview
  • 6.2 Tests/Services
  • 6.3 Kits and Consumables
  • 6.4 Instruments

7 Middle East Liquid Biopsy Market, by Technology, $Million, 2021 - 2032

  • 7.1 Overview
  • 7.2 Polymerase Chain Reaction (PCR)
  • 7.3 Next-Generation Sequencing (NGS)
  • 7.4 Fluorescence In-Situ Hybridization (FISH)
  • 7.5 Other Technologies

8 Middle East Liquid Biopsy Market, by Workflow, $Million, 2021 - 2032

  • 8.1 Overview
  • 8.2 Sample Preparation
  • 8.3 Library Preparation
  • 8.4 Sequencing
  • 8.5 Data Analysis

9 Middle East Liquid Biopsy Market, by Usage, $Million, 2021 - 2032

  • 9.1 Overview
  • 9.2 Research Use Only (RUO)
  • 9.3 Clinical

10 Middle East Liquid Biopsy Market, by Sample, $Million, 2021 - 2032

  • 10.1 Overview
  • 10.2 Blood
  • 10.3 Urine
  • 10.4 Saliva
  • 10.5 Cerebrospinal Fluid

11 Middle East Liquid Biopsy Market, by Circulating Biomarker, $Million, 2021 - 2032

  • 11.1 Overview
  • 11.2 Circulating Tumor Cells (CTCs)
  • 11.3 Cell-Free DNA (cfDNA)
  • 11.4 Circulating Cell-Free RNA
  • 11.5 Exosomes and Extracellular Vesicles
  • 11.6 Other Circulating Biomarkers

12 Middle East Liquid Biopsy Market, by Indication, $Million, 2021 - 2032

  • 12.1 Overview
  • 12.2 Lung Cancer
  • 12.3 Breast Cancer
  • 12.4 Prostate Cancer
  • 12.5 Colorectal Cancer
  • 12.6 Melanoma
  • 12.7 Other Cancers
  • 12.8 Non-Oncology Disorder

13 Middle East Liquid Biopsy Market, by Clinical Application, $Million, 2021 - 2032

  • 13.1 Overview
  • 13.2 Treatment Monitoring
  • 13.3 Prognosis and Recurrence Monitoring
  • 13.4 Treatment Selection
  • 13.5 Diagnosis and Screening

14 Middle East Liquid Biopsy Market, by Country, $Million, 2021-2032

  • 14.1 Overview
    • 14.1.1 K.S.A.
    • 14.1.2 Israel
    • 14.1.3 U.A.E.
    • 14.1.4 Egypt
    • 14.1.5 Iran
    • 14.1.6 Qatar
    • 14.1.7 Rest-of-the-Middle East

15 Market - Competitive Benchmarking & Company Profiles

  • 15.1 Overview
  • 15.2 Bio-Rad Laboratories, Inc.
    • 15.2.1 Company Overview
    • 15.2.2 Role of Bio-Rad Laboratories, Inc. in the Middle East Liquid Biopsy Market
    • 15.2.3 Key Competitors of the Company
    • 15.2.4 Key Customers of the Company
    • 15.2.5 Financials
    • 15.2.6 Key Insights about Financial Health of the Company
    • 15.2.7 SWOT Analysis
  • 15.3 Bioscience Institute S.p.A.
    • 15.3.1 Company Overview
    • 15.3.2 Role of Bioscience Institute S.p.A. in the Middle East Liquid Biopsy Market
    • 15.3.3 Key Competitors of the Company
    • 15.3.4 Key Customers of the Company
    • 15.3.5 SWOT Analysis
  • 15.4 Eurofins Scientific
    • 15.4.1 Company Overview
    • 15.4.2 Role of Eurofins Scientific in the Middle East Liquid Biopsy Market
    • 15.4.3 Key Competitors of the Company
    • 15.4.4 Key Customers of the Company
    • 15.4.5 Business Strategies
    • 15.4.6 Financials
    • 15.4.7 SWOT Analysis
  • 15.5 F. Hoffmann-La Roche Ltd
    • 15.5.1 Company Overview
    • 15.5.2 Role of F. Hoffmann-La Roche Ltd in the Middle East Liquid Biopsy Market
    • 15.5.3 Key Competitors of the Company
    • 15.5.4 Key Customers of the Company
    • 15.5.5 Business Strategies
    • 15.5.6 Financials
    • 15.5.7 Key Insights about Financial Health of the Company
    • 15.5.8 SWOT Analysis
  • 15.6 Guardant Health
    • 15.6.1 Company Overview
    • 15.6.2 Role of Guardant Health in the Middle East Liquid Biopsy Market
    • 15.6.3 Key Competitors of the Company
    • 15.6.4 Key Customers of the Company
    • 15.6.5 Business Strategies
    • 15.6.6 Financials
    • 15.6.7 Key Insights about Financial Health of the Company
    • 15.6.8 SWOT Analysis
  • 15.7 Illumina, Inc.
    • 15.7.1 Company Overview
    • 15.7.2 Role of Illumina, Inc. in the Middle East Liquid Biopsy Market
    • 15.7.3 Key Competitors of the Company
    • 15.7.4 Key Customers of the Company
    • 15.7.5 Financials
    • 15.7.6 Key Insights about Financial Health of the Company
    • 15.7.7 SWOT Analysis
  • 15.8 Natera, Inc.
    • 15.8.1 Company Overview
    • 15.8.2 Role of Natera, Inc. Limited in the Middle East Liquid Biopsy Market
    • 15.8.3 Key Competitors of the Company
    • 15.8.4 Key Customers of the Company
    • 15.8.5 Financials
    • 15.8.6 Key Insights about Financial Health of the Company
    • 15.8.7 SWOT Analysis
  • 15.9 NeoGenomics Laboratories, Inc.
    • 15.9.1 Company Overview
    • 15.9.2 Role of NeoGenomics Laboratories, Inc. in the Middle East Liquid Biopsy Market
    • 15.9.3 Key Competitors of the Company
    • 15.9.4 Key Customers of the Company
    • 15.9.5 Corporate Strategies
    • 15.9.6 Financials
    • 15.9.7 Key Insights about Financial Health of the Company
    • 15.9.8 SWOT Analysis
  • 15.1 PerkinElmer Inc.
    • 15.10.1 Company Overview
    • 15.10.2 Role of PerkinElmer Inc. in the Middle East Liquid Biopsy Market
    • 15.10.3 Key Competitors of the Company
    • 15.10.4 Key Customers of the Company
    • 15.10.5 Financials
    • 15.10.6 Key Insights about Financial Health of the Company
    • 15.10.7 SWOT Analysis
  • 15.11 QIAGEN N.V.
    • 15.11.1 Company Overview
    • 15.11.2 Role of QIAGEN N.V. in the Middle East Liquid Biopsy Market
    • 15.11.3 Key Competitors of the Company
    • 15.11.4 Key Customers of the Company
    • 15.11.5 Financials
    • 15.11.6 Key Insights about Financial Health of the Company
    • 15.11.7 SWOT Analysis
  • 15.12 Sysmex Corporation
    • 15.12.1 Company Overview
    • 15.12.2 Role of Sysmex Corporation in the Middle East Liquid Biopsy Testing Market
    • 15.12.3 Key Competitors of the Company
    • 15.12.4 Key Customers of the Company
    • 15.12.5 Business Strategies
    • 15.12.6 Financials
    • 15.12.7 Key Insights about Financial Health of the Company
    • 15.12.8 SWOT Analysis
  • 15.13 Thermo Fisher Scientific Inc.
    • 15.13.1 Company Overview
    • 15.13.2 Role of Thermo Fisher Scientific Inc. in the Middle East Liquid Biopsy Market
    • 15.13.3 Key Competitors of the Company
    • 15.13.4 Key Customers of the Company
    • 15.13.5 Financials
    • 15.13.6 Key Insights about Financial Health of the Company
    • 15.13.7 SWOT Analysis

List of Figures

  • Figure 1: Middle East Cancer Burden, 2020
  • Figure 2: Middle East Liquid Biopsy Market Segmentation
  • Figure 3: Middle East Liquid Biopsy Market: Research Methodology
  • Figure 4: Primary Research Methodology
  • Figure 5: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 6: Top-Down Approach (Segment-Wise Analysis)
  • Figure 7: Middle East Liquid Biopsy Market, $Million, 2021-2032
  • Figure 8: Share of Patents Filed in the Middle East Liquid Biopsy Market, FY2014-FY2018
  • Figure 9: Liquid Biopsy Patent Analysis, FY2014-FY2018
  • Figure 10: : Patent Expiration Analysis
  • Figure 11: Role of FDA in Advancing Liquid Biopsy
  • Figure 12: Share of Key Developments and Strategies, January 2017-January 2019
  • Figure 13: Share (by Company), January 2017-January 2019
  • Figure 14: Share of Regulatory Accreditations (by Company), January 2017-January 2019
  • Figure 15: Share of Product and Service Launches (by Company), January 2017-January 2019
  • Figure 16: Share of Mergers and Acquisitions (by Company), January 2017-January 2019
  • Figure 17: Approvals (by Company), January 2017-January 2019
  • Figure 18: Middle East Liquid Biopsy Market Dynamics
  • Figure 19: Middle East Cancer Burden, 2020
  • Figure 20: Middle East Liquid Biopsy Market Segmentation (by Product)
  • Figure 21: Share of Middle East Liquid Biopsy Market (by Product), $Million, 2021 and 2032
  • Figure 22: Middle East Liquid Biopsy Market (Tests/Services), $Million, 2021-2032
  • Figure 23: Middle East Liquid Biopsy Market (Kits and Consumables), $Million, 2021-2032
  • Figure 24: Middle East Liquid Biopsy Market (Instruments), $Million, 2021-2032
  • Figure 25: Middle East Liquid Biopsy Market (by Technology)
  • Figure 26: Middle East Liquid Biopsy Market (by Technology), $Million, 2021 and 2032
  • Figure 27: Middle East Liquid Biopsy Market (Polymerase Chain Reaction (PCR)), $Million, 2021-2032
  • Figure 28: Middle East Liquid Biopsy Market (Next-Generation Sequencing (NGS)), $Million, 2021-2032
  • Figure 29: Middle East Liquid Biopsy Market (Fluorescence In-Situ Hybridization (FISH)), $Million, 2021-2032
  • Figure 30: Middle East Liquid Biopsy Market (Other Technologies), $Million, 2021-2032
  • Figure 31: Middle East Liquid Biopsy Market (by Workflow)
  • Figure 32: Middle East Liquid Biopsy Market (by Workflow), $Million, 2021 and 2032
  • Figure 33: Middle East Liquid Biopsy Market (Sample Preparation), $Million, 2021-2032
  • Figure 34: Middle East Liquid Biopsy Market (Library Preparation), $Million, 2021-2032
  • Figure 35: Middle East Liquid Biopsy Market (Sequencing), $Million, 2021-2032
  • Figure 36: Middle East Liquid Biopsy Market (Data Analysis), $Million, 2021-2032
  • Figure 37: Middle East Liquid Biopsy Market (by Usage)
  • Figure 38: Middle East Liquid Biopsy Market (by Usage), $Million, 2021 and 2032
  • Figure 39: Middle East Liquid Biopsy Market (Research Use Only (RUO)), $Million, 2021-2032
  • Figure 40: Middle East Liquid Biopsy Market (Clinical), $Million, 2021-2032
  • Figure 41: Middle East Liquid Biopsy Market (by Sample)
  • Figure 42: Middle East Liquid Biopsy Market (by Sample), $Million, 2021 and 2032
  • Figure 43: Middle East Liquid Biopsy Market (Blood), $Million, 2021-2032
  • Figure 44: Middle East Liquid Biopsy Market (Urine), $Million, 2021-2032
  • Figure 45: Middle East Liquid Biopsy Market (Saliva), $Million, 2021-2032
  • Figure 46: Middle East Liquid Biopsy Market (Cerebrospinal Fluid), $Million, 2021-2032
  • Figure 47: Middle East Liquid Biopsy Market (by Circulating Biomarker)
  • Figure 48: Middle East Liquid Biopsy Market (by Circulating Biomarker), $Million, 2021 and 2032
  • Figure 49: Middle East Liquid Biopsy Market (Circulating Tumor Cells (CTCs)), $Million, 2021-2032
  • Figure 50: Middle East Liquid Biopsy Market (Cell-Free DNA (cfDNA)), $Million, 2021-2032
  • Figure 51: Middle East Liquid Biopsy Market (Circulating Cell-Free RNA), $Million, 2021-2032
  • Figure 52: Middle East Liquid Biopsy Market (Exosomes and Extracellular Vesicles), $Million, 2021-2032
  • Figure 53: Middle East Liquid Biopsy Market (Other Circulating Biomarkers), $Million, 2021-2032
  • Figure 54: Middle East Liquid Biopsy Market (by Indication)
  • Figure 55: Middle East Liquid Biopsy Market (by Indication), $Million, 2021 and 2032
  • Figure 56: Middle East Liquid Biopsy Market (Lung Cancer), $Million, 2021-2032
  • Figure 57: Middle East Liquid Biopsy Market (Breast Cancer), $Million, 2021-2032
  • Figure 58: Middle East Liquid Biopsy Market (Prostate Cancer), $Million, 2021-2032
  • Figure 59: Middle East Liquid Biopsy Market (Colorectal Cancer), $Million, 2021-2032
  • Figure 60: Middle East Liquid Biopsy Market (Melanoma), $Million, 2021-2032
  • Figure 61: Middle East Liquid Biopsy Market (Other Cancers), $Million, 2021-2032
  • Figure 62: Middle East Liquid Biopsy Market (Non-Oncology Disorder), $Million, 2021-2032
  • Figure 63: Middle East Liquid Biopsy Market (by Clinical Application)
  • Figure 64: Middle East Liquid Biopsy Market (by Clinical Application), $Million, 2021 and 2032
  • Figure 65: Middle East Liquid Biopsy Market (Treatment Monitoring), $Million, 2021-2032
  • Figure 66: Middle East Liquid Biopsy Market (Prognosis and Recurrence Monitoring), $Million, 2021-2032
  • Figure 67: Middle East Liquid Biopsy Market (Treatment Selection), $Million, 2021-2032
  • Figure 68: Middle East Liquid Biopsy Market (Diagnosis and Screening), $Million, 2021-2032
  • Figure 69: Middle East Liquid Biopsy Market (by Country), $Million, 2021-2032
  • Figure 70: Middle East Liquid Biopsy Market (by Country), $Million, 2021 and 2032
  • Figure 71: K.S.A. Liquid Biopsy Market, $Million, 2021-2032
  • Figure 72: Israel Liquid Biopsy Market, $Million, 2021-2032
  • Figure 73: U.A.E. Liquid Biopsy Market, $Million, 2021-2032
  • Figure 74: Egypt Liquid Biopsy Market, $Million, 2021-2032
  • Figure 75: Iran East Liquid Biopsy Market, $Million, 2021-2032
  • Figure 76: Qatar Middle East Liquid Biopsy Market, $Million, 2021-2032
  • Figure 77: Rest-of-the-Middle East Liquid Biopsy Market, $Million, 2021-2032
  • Figure 78: Total Number of Companies Profiled
  • Figure 79: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
  • Figure 80: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 81: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 82: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 83: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 84: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 85: Bioscience Institute S.p.A.: Overall Product Portfolio
  • Figure 86: Bioscience Institute S.p.A.: SWOT Analysis
  • Figure 87: Eurofins Scientific: Overall Product Portfolio
  • Figure 88: Eurofins Scientific: Overall Financials, $Million, 2019-2021
  • Figure 89: Eurofins Scientific: Revenue (by Region), $Million, 2019-2021
  • Figure 90: Eurofins Scientific: SWOT Analysis
  • Figure 91: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 92: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
  • Figure 93: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
  • Figure 94: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
  • Figure 95: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
  • Figure 96: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 97: Guardant Health: Overall Product Portfolio
  • Figure 98: Guardant Health: Overall Financials, $Million, 2019-2021
  • Figure 99: Guardant Health: Revenue (by Segment), $Million, 2019-2021
  • Figure 100: Guardant Health: Revenue (by Region), $Million, 2019-2021
  • Figure 101: Guardant Health: R&D Expenditure, $Million, 2019-2021
  • Figure 102: Guardant Health.: SWOT Analysis
  • Figure 103: Illumina, Inc.: Overall Product Portfolio
  • Figure 104: Illumina, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 105: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 106: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 107: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 108: Illumina, Inc.: SWOT Analysis
  • Figure 109: Natera, Inc.: Overall Product Portfolio
  • Figure 110: Natera, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 111: Natera, Inc.: Revenue (by Segment), $Million 2019-2021
  • Figure 112: Natera, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 113: Natera, Inc.: SWOT Analysis
  • Figure 114: NeoGenomics Laboratories, Inc.: Overall Product Portfolio
  • Figure 115: NeoGenomics Laboratories, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 116: NeoGenomics Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 117: NeoGenomics Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 118: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 119: PerkinElmer Inc.: Overall Product Portfolio
  • Figure 120: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
  • Figure 121: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 122: PerkinElmer, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 123: PerkinElmer, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 124: PerkinElmer, Inc.: SWOT Analysis
  • Figure 125: QIAGEN N.V.: Overall Product Portfolio
  • Figure 126: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
  • Figure 127: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
  • Figure 128: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
  • Figure 129: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
  • Figure 130: QIAGEN N.V. N.V.: SWOT Analysis
  • Figure 131: Sysmex Corporation: Overall Product Portfolio
  • Figure 132: Sysmex Corporation: Overall Financials, $Million, 2018-2020
  • Figure 133: Sysmex Corporation: Revenue (by Region), $Million, 2018-2020
  • Figure 134: Sysmex Corporation: R&D Expenditure, $Million, 2018-2020
  • Figure 135: Sysmex Corporation: SWOT Analysis
  • Figure 136: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 137: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
  • Figure 138: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 139: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 140: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 141: Thermo Fisher Scientific Inc.: SWOT Analysis

List of Tables

  • Table 1: Middle East Liquid Biopsy Market: Key Players Patent Portfolio
  • Table 2: Key Players of Liquid Biopsy (Cost Savings)
  • Table 3: Companies Providing Tests/Services
  • Table 4: Companies Providing Kits and Consumables
  • Table 5: Companies Providing Instruments